Ricevi le ultime notizie sulle azioni BioNTech con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di BNTX

Ultime notizie per

BIONTECH SE-ADR

BioNTech

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

Price Action

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

BNTX

CTSH

ORCL

Indizi di risalita e nuove opportunità nel panorama finanziario: ecco le società pronte a sorprendere gli investitori nella prossima seduta.

BioNTech, Oracle e le azioni da monitorare per un lunedì al top

BioNTech SE

Press Releases

Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Small Cap

Opinion

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

BioNTech to Host Innovation Series R&D Day on November 11, 2025

AVAI

CRSP

CVAC

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

JP Morgan

Morgan Stanley

HC Wainwright & Co.

Wells Fargo

B of A Securities

Comments

BioNTech Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO